Interstitial cystitis/bladder pain syndrome (IC/BPS) is a chronic and debilitating urological disorder characterized by pelvic pain, urinary urgency, frequency, and nocturia, often accompanied by bladder pain and discomfort. Despite its prevalence and impact on quality of life, IC/BPS remains a diagnostic and therapeutic challenge for healthcare providers. This review aims to provide a comprehensive overview of IC/BPS, including its epidemiology, pathophysiology, clinical presentation, diagnostic approaches, and management strategies.

Epidemiology: IC/BPS predominantly affects women, with a female-to-male ratio estimated to be around 9:1. While the exact prevalence of IC/BPS varies depending on diagnostic criteria and population studied, it is estimated to affect approximately 2-7% of the general population. IC/BPS can occur across all age groups, but it most commonly presents in individuals aged 30-50 years. The condition is associated with significant healthcare utilization, reduced quality of life, and substantial economic burden due to medical expenses and lost productivity.

Pathophysiology: The pathophysiology of IC/BPS is multifactorial and incompletely understood. Proposed mechanisms include urothelial dysfunction, epithelial barrier disruption, neurogenic inflammation, mast cell activation, autoimmune processes, and pelvic floor dysfunction. Alterations in the glycosaminoglycan layer of the bladder epithelium, aberrant sensory nerve signaling, and central sensitization may contribute to bladder hypersensitivity and pain perception in individuals with IC/BPS. Genetic predisposition, environmental factors, and psychosocial stressors may also play a role in the development and perpetuation of IC/BPS symptoms.

Clinical Presentation: IC/BPS presents with a spectrum of symptoms, including pelvic pain, urinary urgency, frequency, and nocturia, often accompanied by bladder pain or discomfort. Symptoms may be constant or fluctuate in intensity, exacerbating with bladder filling and alleviating with voiding. The clinical presentation of IC/BPS can overlap with other urological conditions such as urinary tract infections, overactive bladder, and chronic pelvic pain syndromes, necessitating a thorough medical history, physical examination, and diagnostic evaluation to establish the diagnosis.

Diagnostic Approaches: The diagnosis of IC/BPS is primarily based on clinical criteria established by the International Continence Society (ICS) and the American Urological Association (AUA). Key features include chronic pelvic pain or discomfort related to the bladder, urinary urgency, frequency, and nocturia, in the absence of identifiable infection or other pathology. Diagnostic evaluation may include urine analysis, urine culture, cystoscopy with hydrodistention, and bladder biopsy to exclude other conditions and confirm the diagnosis of IC/BPS. Symptom diaries, validated questionnaires (e.g., O’Leary-Sant Interstitial Cystitis Symptom Index, Interstitial Cystitis Problem Index), and bladder pain mapping may aid in symptom characterization and monitoring disease progression.

Management Strategies: The management of IC/BPS is individualized and multidisciplinary, incorporating pharmacotherapy, dietary modifications, physical therapy, behavioral interventions, and minimally invasive procedures. Treatment modalities aim to alleviate symptoms, improve bladder function, and enhance quality of life. Pharmacological options may include oral medications (e.g., pentosan polysulfate sodium, anticholinergics, tricyclic antidepressants, antihistamines), intravesical instillations (e.g., dimethyl sulfoxide, heparin, lidocaine), or botulinum toxin injections. Dietary modifications such as avoidance of bladder irritants (e.g., caffeine, alcohol, acidic foods) and adherence to an elimination diet (e.g., low-acid, low-oxalate) may help reduce symptom exacerbations. Physical therapy techniques such as pelvic floor muscle relaxation, biofeedback, and myofascial release can address pelvic floor dysfunction and alleviate pelvic pain. Behavioral interventions, including bladder retraining, stress management, and cognitive-behavioral therapy, may help patients develop coping strategies and improve symptom management skills. In refractory cases, surgical interventions such as bladder augmentation, neuromodulation, or urinary diversion may be considered, although the risks and benefits should be carefully weighed.

Conclusion: Interstitial cystitis/bladder pain syndrome is a complex and multifaceted urological disorder characterized by chronic pelvic pain, urinary urgency, frequency, and bladder discomfort. By understanding the epidemiology, pathophysiology, clinical presentation, diagnostic approaches, and management strategies of IC/BPS, healthcare providers can effectively diagnose, treat, and support patients affected by this debilitating condition. Continued research efforts aimed at elucidating the underlying mechanisms and identifying targeted therapeutic interventions are essential for improving outcomes and enhancing the quality of life for individuals living with IC/BPS. A collaborative and patient-centered approach, incorporating multidisciplinary expertise and personalized care plans, is paramount in optimizing the management of IC/BPS and alleviating the burden of this chronic urological condition.